Drug Development
ONYX-015 and MAP chemotherapy may help some patients with advanced sarcomas
Published in Gene Therapy Weekly, May 5th, 2005
According to a study from the United States, "ONYX-015 is a provisionally replication competent adenovirus with oncolytic activity in cells with malfunctioning p53. Sarcomas represent a rational target for this approach given the high frequency of p53 mutations (40-75%) and MDM-2 amplification (10-30%)."
"We, therefore, undertook a phase I/II study of ONYX-015, days 1-5 every month administered intratumorally under radiographic guidance, in combination with MAP (mitomycin-C, doxorubicin, cisplatin) chemotherapy in patients with advanced sarcoma," said E. Galanis and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-05-05)
More Articles from Gene Therapy Weekly
- Cancer Immunotherapy
Interleukin 12 gene transfer retards fibrosarcoma growth and metastasis - Endocrinology
Limited diffusion impedes the transfection of pituitary tumors - Prostate Cancer
Radiotherapy and sKDR gene delivery demolish malignant prostate tumors - Virology
Pseudotyped lentiviral vector steers therapy to metastatic melanoma - Adverse Drug Reaction
Pre-existing immunity alters host response to systemic adenoviral vector - Allergy & Immunology
Inhaled antisense oligonucleotide alleviates murine asthma - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
